Atenolol 50 mg
Searched over 200M research papers
Summary
10 papers analyzed
These studies suggest atenolol 50 mg is effective for treating hypertension and has comparable efficacy to higher doses, with additional benefits in specific conditions like obstructive sleep apnea and acute myocardial infarction.
Not a yes or no question
To use the Consensus Meter, try asking a simple yes or no question
Research summarized with Copilot
Beta20 papers analyzed
Atenolol 50 mg: Efficacy, Comparisons, and Pharmacokinetics
Efficacy of Atenolol 50 mg in Hypertension Treatment
Atenolol, a cardioselective beta-adrenoceptor antagonist, is widely used in the management of hypertension. Studies have shown that a 50 mg once-daily dose of atenolol effectively reduces blood pressure in patients with mild to moderate hypertension. In a double-blind crossover trial, atenolol 50 mg significantly lowered both lying and standing blood pressure by approximately 23/16 mm Hg and 22/18 mm Hg, respectively, from baseline levels. This reduction was comparable to higher doses of 100 mg and 200 mg, indicating that increasing the dose beyond 50 mg does not provide additional benefits in blood pressure reduction .
Comparative Effectiveness with Other Antihypertensive Agents
When compared to other antihypertensive medications such as amlodipine, enalapril, hydrochlorothiazide, and losartan, atenolol 50 mg demonstrated superior efficacy in lowering office diastolic blood pressure in patients with hypertension and obstructive sleep apnea (OSA). Atenolol also effectively reduced mean nighttime ambulatory diastolic and systolic blood pressure more than amlodipine, enalapril, or losartan, although it was comparable to hydrochlorothiazide in this regard.
Pharmacokinetics and Bioavailability
The pharmacokinetics of atenolol 50 mg have been well-documented. The bioavailability of orally administered atenolol is approximately 50%, with peak plasma concentrations (Cmax) reached within 2 to 2.5 hours post-administration . Studies comparing different formulations of 50 mg atenolol have confirmed their bioequivalence, meaning they can be used interchangeably without significant differences in therapeutic outcomes. The pharmacokinetic parameters such as Cmax, Tmax, and AUC (area under the curve) are consistent with previous studies, ensuring reliable and predictable drug behavior .
Atenolol in Special Populations
Acute Myocardial Infarction
In patients with suspected acute myocardial infarction, early administration of intravenous atenolol followed by oral doses significantly reduced the incidence of ventricular arrhythmias. This protective effect was evident with a reduction in heart rate and fewer patients requiring additional antiarrhythmic agents or digoxin.
Pregnancy
Atenolol use during pregnancy, particularly from the end of the first trimester, has been associated with intrauterine growth retardation. A study comparing atenolol to placebo in pregnant women with mild hypertension found that while atenolol effectively reduced diastolic blood pressure, it also resulted in significantly lower birth weights. This finding suggests caution in prescribing atenolol during pregnancy due to potential adverse effects on fetal growth.
Conclusion
Atenolol 50 mg is an effective and well-tolerated option for managing mild to moderate hypertension, with efficacy comparable to higher doses and other antihypertensive agents. Its pharmacokinetic profile supports consistent therapeutic outcomes, and it is bioequivalent across different formulations. However, caution is advised when prescribing atenolol to pregnant women due to potential risks to fetal development. Overall, atenolol 50 mg remains a valuable tool in the treatment of hypertension, offering significant benefits in blood pressure control and cardiovascular protection.
Sources and full results
Most relevant research papers on this topic
